These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 22692814)

  • 1. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Khan A; Hangartner T; Weinreb NJ; Taylor JS; Mistry PK
    J Bone Miner Res; 2012 Aug; 27(8):1839-48. PubMed ID: 22692814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing selection bias in case-control studies from rare disease registries.
    Cole JA; Taylor JS; Hangartner TN; Weinreb NJ; Mistry PK; Khan A
    Orphanet J Rare Dis; 2011 Sep; 6():61. PubMed ID: 21910867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
    Mistry PK; Deegan P; Vellodi A; Cole JA; Yeh M; Weinreb NJ
    Br J Haematol; 2009 Nov; 147(4):561-70. PubMed ID: 19732054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
    Mistry PK; Weinreb NJ; Kaplan P; Cole JA; Gwosdow AR; Hangartner T
    Blood Cells Mol Dis; 2011 Jan; 46(1):66-72. PubMed ID: 21112800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center.
    Basiri M; Ghaffari ME; Ruan J; Murugesan V; Kleytman N; Belinsky G; Akhavan A; Lischuk A; Guo L; Klinger K; Mistry PK
    Elife; 2023 May; 12():. PubMed ID: 37249220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
    Pastores GM; Elstein D; Hrebícek M; Zimran A
    Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry.
    Rosenbloom B; Balwani M; Bronstein JM; Kolodny E; Sathe S; Gwosdow AR; Taylor JS; Cole JA; Zimran A; Weinreb NJ
    Blood Cells Mol Dis; 2011 Jan; 46(1):95-102. PubMed ID: 21067946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review.
    Tauchmanovà L; De Rosa G; Serio B; Fazioli F; Mainolfi C; Lombardi G; Colao A; Salvatore M; Rotoli B; Selleri C
    Cancer; 2003 May; 97(10):2453-61. PubMed ID: 12733144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone and body composition of children and adolescents with repeated forearm fractures.
    Goulding A; Grant AM; Williams SM
    J Bone Miner Res; 2005 Dec; 20(12):2090-6. PubMed ID: 16294262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
    Piran S; Roberts A; Patterson MA; Amato D
    Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease.
    Magal I; Lebel E; Altarescu G; Itzchaki M; Rudensky B; Foldes AJ; Zimran A; Elstein D
    Br J Haematol; 2006 Apr; 133(1):93-7. PubMed ID: 16512834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Life expectancy in Gaucher disease type 1.
    Weinreb NJ; Deegan P; Kacena KA; Mistry P; Pastores GM; Velentgas P; vom Dahl S
    Am J Hematol; 2008 Dec; 83(12):896-900. PubMed ID: 18980271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Bone Mineral Density by Dual-Energy X-Ray Absorptiometry and Bone Strength by Speed-of-Sound Ultrasonography in Adults With Gaucher Disease.
    Baskin E; Dinur T; Lebel E; Tiomkin M; Elstein D; Zimran A
    J Clin Densitom; 2016 Oct; 19(4):465-470. PubMed ID: 26781431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
    Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential biomarkers of osteonecrosis in Gaucher disease.
    Pavlova EV; Deegan PB; Tindall J; McFarlane I; Mehta A; Hughes D; Wraith JE; Cox TM
    Blood Cells Mol Dis; 2011 Jan; 46(1):27-33. PubMed ID: 21075651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-reported fractures and associated factors in women with systemic lupus erythematosus.
    Lee C; Almagor O; Dunlop DD; Manzi S; Spies S; Ramsey-Goldman R
    J Rheumatol; 2007 Oct; 34(10):2018-23. PubMed ID: 17787041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline characteristics of 32 patients with Gaucher disease who were treated with imiglucerase: South African data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Sevittz H; Laher F; Varughese ST; Nel M; McMaster A; Jacobson BF
    S Afr Med J; 2022 Feb; 112(1):13518. PubMed ID: 35140000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantation.
    McAvoy S; Baker KS; Mulrooney D; Blaes A; Arora M; Burns LJ; Majhail NS
    Biol Blood Marrow Transplant; 2010 Sep; 16(9):1231-6. PubMed ID: 20302963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
    J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.